Login Register
icon_bulk_orderBulk order Acrobiosystems for English
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > 2019-nCoV proteins > Spike protein > RAS-A039

SARS-CoV-2 Spike Protein ELISA Kit (For Vaccine Development)

For research use only.
Materials Provided
IDComponentsSize
RAS039-C01Pre-coated Anti-SARS-CoV-2 Spike Protein Antibody Microplate1 plate
RAS039-C02SARS-CoV-2 Spike Protein10 ug
RAS039-C03HRP-Anti-SARS-CoV-2 Spike Protein Antibody20 ug
RAS039-C0410xWashing Buffer 50 mL
RAS039-C05Dilution Buffer50 mL
RAS039-C06Substrate Solution12 mL
RAS039-C07Stop Solution7 mL
  • Background
    The newly identified Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has posed a serious threat to human health. A rapid and effective assay kit detecting the levels of SARS-CoV-2 Spike protein is urgently needed to accelerate the development of COVID-19 vaccines.
  • Application
    This kit is developed for detecting SARS-CoV-2 Spike Protein in vaccine samples,witch is the low sensitivity version of Cat.No. RAS-A020.The kit can meet the needs of vaccine developers to establish antigen quantification methods for preclinical evaluation, vaccine production and quality control,and realize accurate quantification of vaccine antigen contents for COVID-19 vaccines of all technological platforms, multivalent vaccines, and VOC-specific boosters.
    It is for research use only.
  • Reconstitution
    Please see Certificate of Analysis for details of reconstitution instruction and specific concentration.
  • Storage

    The unopened kit is stable for 12 months from the date of manufacture if stored at 2°C to 8°C.

    The opened kit should be stored per components table. The shelf life is 30 days from the date of opening.

  • Assay Principles
    This assay kit employs a standard sandwich-ELISA format, providing a rapid detection of SARS-CoV-2 Spike Protein. The kit consists of microplate pre-coated with Anti-SARS-CoV-2 Spike protein Antibody, an SARS-CoV-2 Spike Protein as Control, an HPR-Anti-SARS-CoV-2 Spike protein Antibody,and buffers.

    Your experiment will include 5 simple steps:

    a) All reagents were returned to room temperature (20℃-25℃) before use.

    b) Add your sample to the plate, take the SARS-CoV-2 Spike protein as Control sample. The samples and Control sample are diluted by Dilution Buffer.

    c) Add a diluted HRP-Anti-SARS-CoV-2 Spike Protein Antibody to the plate. The diluted by Dilution Buffer.

    d) Wash the plate and add TMB.

    e) Stop the substrate reaction by add diluted acid. Absorbance (OD) is calculate as the absorbance at 450 nm minus the absorbance at 630 nm to remove background prior to statistical analysis. The OD Value reflects the amount of protein bound.

Typical Data
SARS-CoV-2 Spike Protein ELISA Kit (For Vaccine Development)SARS-CoV-2 Spike Protein ELISA Kit (For Vaccine Development) (Cat. No. RAS-A039) ELISA bioactivity

Immobilized Anti-SARS-CoV-2 Spike Protein Antibody at 2 μg/mL (100 μL/well) can bind SARS-CoV-2 Spike Protein. Detection was performed using HRP-Anti-SARS-CoV-2 Spike Protein Antibody with sensitivity of 20 ng/mL (QC tested).

SARS-CoV-2 Spike Protein ELISA Kit (For Vaccine Development)SARS-CoV-2 Spike Protein ELISA Kit (For Vaccine Development) (Cat. No. RAS-A039) ELISA bioactivity

SARS-CoV-2 Spike Protein ELISA Kit (For Vaccine Development)(Cat.No.RAS-A039) can potently to detect the all SARS-CoV-2 Variants of Concern (VOCs), including Alpha (Cat.No.SPN-C52H6), Beta (Cat.No.SPN-C52Hk), Gamma (Cat.No.SPN-C52Hg) and Delta (Cat.No.SPN-C52He).

SARS-CoV-2 Spike Protein ELISA Kit (For Vaccine Development)SARS-CoV-2 Spike Protein ELISA Kit (For Vaccine Development) (Cat. No. RAS-A039) ELISA bioactivity

SARS-CoV-2 Spike Protein ELISA Kit (For Vaccine Development) (Cat.No.RAS-A039) can potently to detect the all SARS-CoV-2 Variants of Concern (VOCs), including Omicron (Cat.No.SPN-C52Hz).

Comments (0)


ETD of in-stock products: 2 business days

Price(USD) : $580.00

Promotion & Exhibitions



Drug Development Status

  • Number of Launched Drugs:1 Details
  • Number of Drugs in Clinical Trials:3 Details
  • Latest Research Phase:Approved

Datasheet & Documentation

Request for DMF
DMF (Drug Master File)

Contact Us

+1  800-810-0816 (US)
+86 400-682-2521 (AP)

New Product Launch

Questions & Comments

This web search service is supported by Google Inc.

totop
Call us
Call us
North America: +1 800-810-0816 (Toll Free)
Asia & Pacific: +86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA

Leave a message